IOVANCE BIOTHERAPEUTICS, INC. Quarterly Accounts Payable, Current in USD from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Iovance Biotherapeutics, Inc. quarterly Accounts Payable, Current history and growth rate from Q4 2010 to Q3 2024.
  • Iovance Biotherapeutics, Inc. Accounts Payable, Current for the quarter ending September 30, 2024 was $31.7M, a 64.4% increase year-over-year.
Accounts Payable, Current, Quarterly (USD)
Accounts Payable, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $31.7M +$12.4M +64.4% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $20.4M -$10.7M -34.5% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $25.7M -$5.87M -18.6% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $33.1M +$6.52M +24.5% Dec 31, 2023 10-Q 2024-11-07
Q3 2023 $19.3M -$4.98M -20.5% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $31.2M +$11.1M +55.7% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $31.6M +$11.1M +54.4% Mar 31, 2023 10-Q 2023-05-10
Q4 2022 $26.6M -$774K -2.83% Dec 31, 2022 10-K 2024-02-28
Q3 2022 $24.3M +$12.1M +99.1% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 $20M -$1.91M -8.69% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $20.5M +$7.09M +53% Mar 31, 2022 10-Q 2022-05-05
Q4 2021 $27.4M +$13.9M +103% Dec 31, 2021 10-K 2023-02-28
Q3 2021 $12.2M -$12.6M -50.9% Sep 30, 2021 10-Q 2021-11-04
Q2 2021 $21.9M +$11.7M +114% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $13.4M +$2.76M +26% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $13.5M -$2.05M -13.2% Dec 31, 2020 10-K 2022-02-24
Q3 2020 $24.8M +$14.9M +150% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $10.2M -$2.54M -19.9% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 $10.6M +$3.03M +39.9% Mar 31, 2020 10-Q 2020-05-05
Q4 2019 $15.6M +$12.8M +468% Dec 31, 2019 10-K 2021-02-25
Q3 2019 $9.92M +$3.91M +65% Sep 30, 2019 10-Q 2019-11-04
Q2 2019 $12.8M +$7.59M +146% Jun 30, 2019 10-Q 2019-08-01
Q1 2019 $7.59M +$1.01M +15.4% Mar 31, 2019 10-Q 2019-05-07
Q4 2018 $2.74M +$1.51M +122% Dec 31, 2018 10-K 2020-02-25
Q3 2018 $6.01M +$3.11M +107% Sep 30, 2018 10-Q 2018-11-06
Q2 2018 $5.2M +$1.5M +40.6% Jun 30, 2018 10-Q 2018-08-07
Q1 2018 $6.58M +$4.4M +202% Mar 31, 2018 10-Q 2018-05-10
Q4 2017 $1.23M +$369K +42.8% Dec 31, 2017 10-K 2019-02-28
Q3 2017 $2.91M +$2.68M +1174% Sep 30, 2017 10-Q 2017-11-02
Q2 2017 $3.7M +$2.97M +410% Jun 30, 2017 10-Q 2017-08-03
Q1 2017 $2.17M +$1.12M +106% Mar 31, 2017 10-Q 2017-05-03
Q4 2016 $863K -$95K -9.92% Dec 31, 2016 10-K 2018-03-12
Q3 2016 $228K -$933K -80.4% Sep 30, 2016 10-Q 2016-11-04
Q2 2016 $725K -$432K -37.3% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 $1.05M -$53.4K -4.82% Mar 31, 2016 10-Q 2016-05-09
Q4 2015 $958K -$290K -23.2% Dec 31, 2015 10-K 2017-03-09
Q3 2015 $1.16M +$587K +102% Sep 30, 2015 10-Q 2015-11-06
Q2 2015 $1.16M +$716K +163% Jun 30, 2015 10-Q 2015-08-10
Q1 2015 $1.11M +$821K +287% Mar 31, 2015 10-Q 2015-05-11
Q4 2014 $1.25M +$835K +202% Dec 31, 2014 10-K 2016-03-11
Q3 2014 $574K -$977K -63% Sep 30, 2014 10-Q 2014-11-13
Q2 2014 $441K -$1.04M -70.3% Jun 30, 2014 10-Q 2014-08-08
Q1 2014 $286K -$1.01M -77.8% Mar 31, 2014 10-Q 2014-05-14
Q4 2013 $413K -$685K -62.4% Dec 31, 2013 10-K 2015-03-16
Q3 2013 $1.55M +$709K +84.3% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 $1.48M +$872K +143% Jun 30, 2013 10-Q 2013-10-23
Q1 2013 $1.29M +$787K +156% Mar 31, 2013 10-Q 2013-10-23
Q4 2012 $1.1M +$908K +478% Dec 31, 2012 10-K 2014-03-28
Q3 2012 $842K +$635K +307% Sep 30, 2012 10-Q 2013-01-25
Q2 2012 $609K +$479K +366% Jun 30, 2012 10-Q/A 2012-09-10
Q1 2012 $504K Mar 31, 2012 10-Q 2012-05-15
Q4 2011 $190K +$160K +527% Dec 31, 2011 10-K 2013-09-23
Q3 2011 $207K Sep 30, 2011 10-Q 2011-11-21
Q2 2011 $131K Jun 30, 2011 10-Q/A 2011-09-01
Q4 2010 $30.3K Dec 31, 2010 10-K 2012-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.